APA (7th ed.) Citation

TT, H., JB, P., R, G., JK, H., RA, M., K, D., . . . H, E. (2024). Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics, 25(1), 29. https://doi.org/10.2217/pgs-2023-0204

Chicago Style (17th ed.) Citation

TT, Ho, et al. "Association Between CYP3A4, CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients." Pharmacogenomics 25, no. 1 (2024): 29. https://doi.org/10.2217/pgs-2023-0204.

MLA (9th ed.) Citation

TT, Ho, et al. "Association Between CYP3A4, CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients." Pharmacogenomics, vol. 25, no. 1, 2024, p. 29, https://doi.org/10.2217/pgs-2023-0204.